The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I CITN-12: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm. Cancer Immunotherapy Trials Network; Uldrick, Thomas S. (301) 402-6296... […]
AARP published a report detailing how retail prices for over one hundred widely used specialty prescription drugs surged skyward by nearly 11 percent in 2013, surpassing the median income of an American family.
THE INTERNATIONAL CANCER GENOME CONSORTIUM made 1,200 encrypted cancer whole genome sequences available on the Amazon Web Services Cloud for access by cancer researchers worldwide.
Eli Lilly and Company and Merck extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a phase III study in first-line nonsquamous non-small cell lung cancer. The study will be sponsored by Merck and will be open to patients with... […]
STEVEN ROSEN, provost and chief scientific officer for City of Hope, will receive a Lifetime Achievement Award from the Israel Cancer Research Fund, the largest organization in North America devoted solely to supporting cancer research in Israel.
FDA approved Ninlaro (ixazomib), developed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor. The approval was based on an improvement... […]
ALEXANDRA LEVINE was awarded the Hospital Physician Leadership Award by the Los Angeles County Medical Association. Levine is the chief medical officer of City of Hope.
MICHAEL LANG was named chief product development officer for the Cancer Prevention and Research Institute of Texas. Lang will lead CPRIT's product development research program.
FDA granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
PHILIP KANTOFF was named chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center.
